Skip to main content

Advertisement

Table 5 Comparison of neoadjuvant trials with AC followed by docetaxel with or without S-1

From: S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial

Trials Patients Regimen pCR
   Tumor cLN+   Breast + LN Breast
  Stage >4 cm (%)   +CIS* –CIS** +CIS –CIS
This study T1-4c, N1-3 45% 100% AC→SD 22.5% NA 30.6% 22.5%
NSAPB B-27 [3] T1c-3, N0-1 45% 30% AC 11.5% NA 13.7% 9.6%
   45% 30% AC→D 21.8% NA 26.1% 18.9%
GEPARDUO [13] T2-3, N0-2 32% 38% AD NA 7.0% 11.0% 7.0%
   33% 42% AC→D NA 14.3% 22.3% 15.9%
  1. A, doxorubicin; C, cyclophosphamide; CIS, carcinoma in situ; cLN, clinically detected lymph node; D, docetaxel; NA, non-assessable; S, S-1. ‘* + CIS’ or ‘**–CIS’ indicates that the definition of pCR includes or does not include CIS.